Interv Akut Kardiol 2011; 10(5-6): 211-212

Noradrenalin a kardiogenní šok: čas na rehabilitaci?

Ivo Varvařovský
Kardio-Troll, pracoviště invazivní kardiologie, Krajská nemocnice, Pardubice

Editorial k článku Kovářík A, Šulda M, Šnorek M, Toušek F. Postavení noradrenalinu mezi vazopresory v léčbě kardiogenního šoku komplikujícího

akutní infarkt myokardu. Interv Akut Kardiol 2011; 10(5–6): 223–224.

Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I. Noradrenalin a kardiogenní šok: čas na rehabilitaci? Interv Akut Kardiol. 2011;10(5-6):211-212.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Van de Werf F, Bax J, Betriu A. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008; 29: 2909-2945. Go to original source... Go to PubMed...
    2. Widimský P, Hlinomaz O, Kala P. Diagnostika a léčba akutního infarktu myokardu s elevacemi ST. Cor Vasa 2009; 51: 724-740. Go to original source...
    3. Richardt D, Dendorfer A, Tolg R. Inhibition of nonexocytotic norepinephrine release by desipramine reduces myocardial infarction size. Can J Physiol Pharmacol 2006; 84: 1185-1189. Go to original source... Go to PubMed...
    4. Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med 2011; 183: 847-855. Go to original source... Go to PubMed...
    5. Levy B, Perez P, Perny J. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomised pilot study. Crit Care Med 2011; 39: 450-455. Go to original source... Go to PubMed...
    6. Holmes CL. Vasoactive drugs in the intensive care unit. Curr Opin Crit Care 2005; 11: 413-417. Go to original source... Go to PubMed...
    7. How OJ, Rosner A, Kildal AB. Dobutamine-norepinephrine, but not vasopressin, restores the ventriculoarterial matching in experimental cardiogenic shock. Transl Res 2010; 156: 273-281. Go to original source... Go to PubMed...
    8. Rokyta R, Tesarova J, Pechman V. The effects of short-term norepinephrine up-titration on hemodynamics in cardiogenic shock. Physiol Res 2010; 59: 373-378. Go to original source...
    9. Myburgh JA. Catecholamines for shock: the quest for highquality evidence. Crit Care Resusc 2007; 9: 352-356. Go to PubMed...
    10. De Backer D, Biston P, Devriendt J. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362: 779-789. Go to original source... Go to PubMed...
    11. Patel GP, Grahe JS, Sperry M. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 2010; 33: 375-380. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.